2018 Webcasts

Webcasts from HIV Glasgow are being added to the Congress website as and when approvals are received. We will continue to populate this page with more information as it becomes available.

Sunday 28 October
Monday 29 October
Tuesday 30 October
Wednesday 31 October

Sunday 28 October

Interactive Case Study Session
In collaboration with the University of Liverpool Drug Interactions website:
www.hiv-druginteractions.org

HIV pharmacology in 2018 Webcast coming soon
Saye Khoo, Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

Case 1: TB co-infection Webcast
Marta Boffito, HIV and Sexual Health – Kobler Clinic, Chelsea Westminster Hospital, London, UK

Case 2: HIV-HCV and PWIDS
Erica Peters, Brownlee Centre for Infectious Diseases, NHS Greater Glasgow Clyde, Glasgow, UK

Case 3: Pregnancy Webcast
Mas Chaponda, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK

Discussants: Fiona Marra, Advanced Pharmacist HIV/HCV, Gartnavel Hospital, Glasgow, UK
Mohammed Lamorde, Infectious Diseases Institute, Makerere University,
Kampala, Uganda

Jonathan Schapiro, National Hemophilia Center, Sheba Medical Center,
Tel Aviv, Israel

Official Opening Webcast coming soon
Andrew Phillips, University College London, London, UK

Welcome from Glasgow City  Webcast coming soon
Bailie Ade Aibinu, Glasgow City Council, Glasgow, UK

Opening Scientific Session
Co-Chairs:Praphan Phanuphak, Thai Red Cross Research Centre, Bangkok, Thailand
Andrew Phillips

Celebrating a Champion of the Response to HIV Webcast
Remembering David Cooper
Tribute by: Sean Emery, University of New South Wales, Sydney, Australia

Joep Lange and Jacqueline van Tongeren Memorial Lecture: Introduction
Introduction by: Praphan Phanuphak Webcast

Joep Lange and Jacqueline van Tongeren Memorial Lecture: HIV/AIDS, global health and the Sustainable Development Goals Webcast
Kevin M De Cock, CDC Country Office, Nairobi, Kenya
Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of their commitment and passion to rid the world of HIV/AIDS

Strategies to reduce HIV incidence in Europe Webcast
Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

PrEP: what’s happening in Europe and the World in general  Webcast
Sheena McCormack, MRC Clinical Trials Unit at UCL, London, UK

Back to the top of the page

Monday 29 October

Living Well with HIV: Ongoing Challenges
Co-Chairs:Peter Reiss, Department of Global Health, Amsterdam UMC, University of
Amsterdam, Amsterdam, The Netherlands
Caroline Sabin, Institute for Global Health, University College London,
London, UK

Retention and re-engagement in care: a combination approach again
required Webcast

Fiona Burns, Centre for Sexual Heath and HIV Research, and Royal Free Hospital, London, UK

HIV and ageing: challenges and goals Webcast
Julian Falutz, Department of Medicine, McGill University, Montreal, Canada

48-week changes in biomarkers in subjects with high cardiovascular risk switching from ritonavir-boosted protease inhibitors to dolutegravir: the NEAT022 study Webcast
Esteban Martinez, Infectious Disease, Hospital Clínic & University of Barcelona, Barcelona, Spain

Risk of hospitalisation according to gender, sexuality and ethnicity among people with HIV in the modern ART era Webcast
Sophia Rein, Institute for Global Health, University College London, London, UK

Multimorbidity and risk of death differs by gender in people living with HIV in the Netherlands: the ATHENA cohort study Webcast
Ferdinand Wit, Stichting HIV Monitoring, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands

The economic burden of comorbidities among people living with HIV in Germany: a cohort analysis using health insurance claims data Webcast
Eva Wolf, MUC Research, Munich, Germany

Discussion Webcast

In Memory of Mark Wainberg Webcast
Mark made an enormous contribution to both the basic science and global politics of the HIV epidemic. He was a president of the International AIDS Society, received Canada’s highest civilian award and was an extremely active member of the scientific committee of HIV Glasgow for over 20 years.
Tribute by: Ian Weller, University College London, London, UK

Lock Lecture
HIV Glasgow is honoured to have been chosen by the Royal College of Physicians and Surgeons of Glasgow to present the Lock Lecture as part of the Scientific Programme

Lock Lecture: introduction Webcast
David Galloway, President, Royal College of Physicians and Surgeons of Glasgow, Glasgow, UK

STIs among MSM: new challenges in prevention, diagnosis and treatment Webcast
Jean-Michel Molina, Department of Infectious Diseases and University of Paris 7, St Louis Hospital, Paris, France

Comorbidities: Lunchtime Poster Discussion Session
Co-Chairs:Georg Behrens, Department for Clinical Immunology and Rheumatology, Hannover
Medical School, Hannover, Germany
Sarah Pett, UCL Institute of Clinical Trials and Methodology, London, UK

Incidence and risk factors associated with osteoporosis-related fractures (ORF) among PLWHIV in British Columbia (BC), Canada Webcast
José Barletta, Infectious Diseases Division, Hospital Juan A. Fernández, Buenos Aires, Argentina

Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60 Webcast
Franco Maggiolo, USC Malattie Infettive, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo Italy

Haematological manifestations in virologically-suppressed people living with HIV Webcast
Delal Akdag, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

Increases in lipid profile after switch from TDF to TAF-based HAART regimens in a cohort of HIV-positive patients: is it clinically relevant? Webcast
Lidia Gazzola, Infectious Disease, ASST Santi Paolo e Carlo, Milan, Italy

Factors associated with HIV-associated neurocognitive disorder in an unselected cohort in East and South London: the HAND study Webcast
Simon Rackstraw, HIV, Barts Health NHS Trust, London, UK

Substances, Drugs and Outcomes: Lunchtime Poster Discussion Session
Co-Chairs:Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town,
Cape Town, South Africa, and Immediate Past-President, IAS
Simon Collins, HIV i-Base, London, UK

Risky Alcohol Consumption and Associated Health Behaviour among HIV-positive and HIV-negative Patients in a UK Sexual Health and HIV Clinic: the HAZAL Study Webcast
Emmi Suonpera, Institute for Global Health, University College London, London, UK

Chemsex drugs on the rise among MSM: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017 Webcast
Benjamin Hampel, Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland

Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid (Spain): a population-based study 
Juan Berenguer, Instituto de Investigacion Sanitaria, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies Webcast
Rajith Rajoli, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

Cumulative safety review of elvitegravir and bictegravir use during pregnancy and risk of neural tube defects Webcast
Terry Farrow, Pharmacovigilance & Epidemiology, Gilead Sciences, Foster City, CA, USA

Drug Interactions, ARV Toxicity and Switching
Co-Chairs:Anastasia Antoniadou, Division of Internal Medicine IV, National and
Kapodistrian, University of Athens, Athens, Greece
David Back, Molecular and Clinical Pharmacology, University of Liverpool, UK

The top 10 DDIs in day to day clinical management of HIV Webcast
Catia Marzolini, Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland

Adverse effects of current ARVs: myths and realities
Paddy Mallon, Mater Misericordiae University Hospital, Dublin

Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP (n=15,678) Webcast
Victoria Pilkington, Faculty of Medicine, Imperial College London, London, UK

Dual therapy with PI/r+3TC or PI/r+TDF shows non-inferior HIV RNA suppression and lower rates of discontinuation for adverse events, versus triple therapy. Meta-analysis of seven randomised trials in 1624 patients Webcast Poster
Zara Liew, Faculty of Medicine, Imperial College London, London, UK

No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial Webcast
Babafemi Taiwo, Division of Infectious Diseases, Northwestern University, Chicago, IL, USA

Challenging Cases in HIV Treatment and Prevention Webcast coming soon
In collaboration with the International Antiviral Society-USA (IAS-USA)
Moderators:Carlos del Rio, Rollins School of Public Health, Atlanta, GA, USA
Ian Williams, Institute for Global Health, University College London,
London, UK

Welcome and introduction Webcast
Carlos del Rio

Case 1: PrEP Webcast
Roy M Gulick, Weill Cornell Medicine, New York, NY, USA and Carlos del Rio

Case 2: ART: initiating treatment Webcast
Chloe Orkin, Ambrose King Centre, Royal London Hospital, London, UK

Case 3: ART: treatment failure?
Manuel Battegay, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland

Closing remarks Webcast
Ian Williams

Back to the top of the page

Tuesday 30 October

Approaches to Treatment and Cure
Co-Chairs:Giulia Marchetti, Dept of Health Sciences, Clinic of Infectious Diseases,
University of Milan, Milan, Italy
Jonathan Schapiro

Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: Week 96 Webcast
Hans-Jürgen Stellbrink, ICH Study Center, Hamburg, Germany

Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in antiretroviral treatment (ART)-naïve, HIV-1-infected adults: AMBER Week 96 results Webcast
Chloe Orkin, Barts Health NHS Trust and Queen Mary University of London, London, UK

Comparable viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy Webcast
Babafemi Taiwo, Division of Infectious Diseases, Northwestern University, Chicago, IL, USA

The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients Webcast
Flaminia Olearo, Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland

Approaches towards a cure for HIV Webcast
Sarah Fidler, Department of GUM and HIV Medicine, Imperial College and Imperial College NHS Trust, London UK

HIV cure and cancer immunotherapy: cross-disciplinary research at its best Webcast
Steven G Deeks, Department of Medicine, University of California, San Francisco, CA, USA 

Quality of Life Across Different Age Groups of People Living with HIV: A Community Perspective
In collaboration with the European AIDS Treatment Group (EATG)
Co-Chairs:Lene Ryom, Centre of Excellence for Health, Immunity and
Infections, Copenhagen, Denmark
Alain-Volny Anne, Paris, France

Introduction and Project Overview Webcast
Koen Block, EATG, Brussels, Belgium

People living with HIV/AIDS aged 50+ Webcast
Brian West, EATG, Edinburgh, UK
Giovanni Guaraldi, Infectious Diseases, Univesity of Modena and Reggio Emilia, Modena, Italy

Children and adolescents (aged 0-25) Webcast
Sanja Belak Skugor, University Hospital for Infectious Disease, Zagreb, Croatia
Caroline Foster, Imperial College NHS Trust, London, UK

People who have lived with HIV/AIDS at least 10 years (aged 18-50) Webcast
Jackie Morton, EATG, UK
Ferdinand Wit

Panel Discussion Webcast
Georg Behrens, Nikos Dedes, EATG, Athens, Greece, Koen Block, Sanja Belak Skugor

#Adolescent Lives Matter
In collaboration with the International AIDS Society (IAS)
Moderators:Yana Panfilova, Student, Academy of Labour, Social Work and Tourism, Kiev,
Ukraine, and HIV activist and founder of Teenergizer, a youth movement
Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town,
Cape Town, South Africa, and Immediate Past-President, IAS

Living with it: complications of long term HIV Webcast
Rashida Ferrand, London School of Hygiene and Tropical Medicine, London, UK, and Harare, Zimbabwe 

Taking it: PrEP experiences among adolescent MSM Webcast
Sybil Hosek, John Stroger Hospital of Cook Country, Chicago, IL, USA

Staying with it: novel ways to increase adolescent adherence Webcast
Caroline Foster

Dealing with it: mental health and stigma: report from a cohort of YPLHIV in the Ukraine Webcast
Heather Bailey, Population, Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK 

Adolescent friendly – really? Webcast
Mercy Ngulube, Chair, Children’s HIV Association’s Youth Committee, UK

Panel Discussion Webcast

Mental Health and HIV: what we all need to know
In collaboration with the British HIV Association (BHIVA)
Co-Chair:Tamás Bereczky, European AIDS Treatment Group, Budapest, Hungary
Chloe Orkin, Ambrose King Centre, Royal London Hospital,
London, UK; and Chair, BHIVA

Introduction Webcast
Chloe Orkin

Prevalence of mental health problems among people living with HIV Webcast
Fiona Lampe, Infection & Population Health, University College London, London, UK

BHIVA Mental Health Audit Webcast
Chloe Orkin

Discrimination in EU healthcare: the community perspective Webcast
Yonatan Shimells, AIDES, Paris, France

Important DDIs: to include QT/PR interval concerns Webcast
Laura Waters, Mortimer Market Centre, University College London Hospitals, London, UK

Q & A Webcast
All

Back to the top of the page

Wednesday 31 October

HIV and Migration: a renewed challenge
Co-Chair:Karine Lacombe, Infectious and Tropical Diseases Department, Saint-Antoine
Hospital (AP-HP), Paris, France
Stefan Mauss, Center for HIV and Hepatogastroenterology, Düsseldorf, Germany

HIV and migration: a renewed challenge Webcast
Julia Del Amo, National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain

Co-infections: TB and Viral Hepatitis
HIV-associated tuberculosis: diagnosis, management and prevention Webcast
Graeme Meintjes, University of Cape Town, Cape Town, South Africa

Eliminating hepatitis C: a public health perspective Webcast will be available after 16 November
Margaret Hellard, Burnet Institute, Melbourne, Australia; and Viral Hepatitis Services, Department of Infectious Diseases, The Alfred Hospital Melbourne, Australia 

Minimum prices of generic hepatitis C direct acting antivirals fall below US$50 per person cured Webcast Poster
Andrew Hill, Translational Medicine, University of Liverpool, Liverpool, UK

Long-term follow-up of HIV-HBV co-infected patients according to the use of anti-HBV active drugs Webcast
Andrea Calcagno, Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy

What Women Want
Joint session in collaboration with the European AIDS Clinical Society (EACS) and Women Against Viruses in Europe (WAVE)
Co-Chairs:Justyna D Kowalska, Hospital for Infectious Diseases, Medical
University of Warsaw, Warsaw, Poland
Fiona Mulcahy, Department of Genito-Urinary Medicine & Infectious
Diseases, St James’ Hospital, Dublin, Ireland

PrEP for women in Europe: case presentation and lecture Webcast
Agnieszka Wroblewska, HIV Out-Patient CLinic, Hospital for Infectious Diseases, Warsaw, Poland 
Nneka Nwokolo, Sexual Health and HIV Medicine, Chelsea and Westminster Hospital, London, UK

Pharmacokinetic studies in women and its impact on clinical practice: case presentation and lecture Webcast
Eugénie Colin-Benoit, Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland
Karoline Aebi-Popp, Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland

HCV treatment and pregnancy: case presentation and lecture Webcast
Marta Vasylyev, Out Patient Department, Lviv Regional AIDS Center, Lviv, Ukraine
Karine Lacombe, Infectious and Tropical Diseases Department, Saint Antoine Hospital (AP-HP), Paris, France

Higher rate of virological failure in women compared to men when starting dual antiretroviral treatment: sex-specific analysis from the Frankfurt HIV Cohort Webcast
Benjamin Koenigs, HIV Center, University Hospital Frankfurt, Frankfurt, Germany

Successes and emerging challenges in prevention of vertical HIV transmission in the UK and Ireland Webcast
Helen Peters, Great Ormond Street Institute of Child Health, University College London, London, UK

HCV co-infection is a strong risk factor for pre-term birth among HIV-positive women on cART – data from HIV Out-Patient Clinic in Warsaw Webcast
Karolina Nowicka, Medical University of Warsaw, Hospital for Infectious Diseases, Warsaw, Poland

ART: Lunchtime Poster Discussion Session
Co-Chairs:Nadia Ahmed, Centre of Excellence for Adolescents Health and
Wellbeing, Desmond Tutu HIV Foundation and Faculty of Health
Sciences, University of Cape Town, Cape Town, South Africa
Ian Williams

High prevalence of previously undocumented baseline M184V/I does not affect virologic outcome in virologically-suppressed patients switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from a boosted-protease inhibitor-based regimen Webcast
Richard Haubrich, Medical Affairs, Gilead Sciences, Foster City, CA, USA

Comparison of viral replication below 50c/mL for two drug (DTG+RPV) versus three drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and SWORD-2 studies Webcast
Mark Underwood, Clinical Virology, ViiV Healthcare, Research Triangle Park, NC, USA

Safety, efficacy and durability of long-acting CAB and RPV as two-drug IM maintenance therapy for HIV-1 infection: LATTE-2 Week 160 results Webcast
David Margolis, Clinical Development, ViiV Healthcare, Research Triangle Park, NC, USA

Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naïve adults with HIV-1 infection: subgroup analyses in the GEMINI studies Webcast
Chloe Orkin, Barts Health NHS Trust and Queen Mary University of London, London, UK

Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort Webcast
Alessandra Vergori, L.Spallanzani, IRCCS HIV/AIDS Unit, National Institute for Infectious Diseases, Rome, Italy

An HIV outbreak among people who inject drugs in Glasgow
Co-Chairs:Andrew Leigh Brown, University of Edinburgh, Edinburgh, UK
Emma Thomson, Centre for Virus Research, Institute of Infection,
Immunity & Imflammation, Glasgow, UK

Introduction Webcast
Andrew Leigh Brown

Using real-time phylodynamic analysis to assess and guide public health interventions in an HIV outbreak among PWIDs in Scotland
Amanda Bradley-Stewart, Virology, NHS Greater Glasgow and Clyde, Glasgow, UK

Is early ART achievable in PWIDs living with HIV?
Rebecca Metcalfe, NHS Greater Glasgow and Clyde Brownlee Centre, Gartnavel General Hospital, Glasgow, UK

An outbreak of HIV amongst homeless PWIDs: an innovative HIV clinical service model adaptation leading to successful clinical outcomes
Erica Peters

Providing HIV ARVs via community pharmacies alongside opiate replacement therapy (ORT) during an HIV outbreak amongst PWIDs Webcast
Regina O’Hara, Brownlee Outpatients, Gartnavel General Hospital, Glasgow, UK

Nurses at the forefront: a new HIV service model for PWIDs in Glasgow 
Patricia Anderson, Brownlee Centre, Gartnavel General Hospital, Glasgow, UK

Panel Discussion

Late Breakers/Hot Topics
Co-Chairs:Deniz Gökengin, Department of Infectious Diseases and Clinical Microbiology
Microbiology, Faculty of Medicine, Ege University, Izmir, Turkey

Roy M Gulick

New ARV drugs and strategies Webcast
Alexandra Calmy, HIV/AIDS Unit, Geneva University Hospitals, Geneva, Switzerland

Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial Webcast
Eric Delaporte, TransVIHMI et CHU Montpellier IRD-INSERM, Université Montpellier, Montpellier, France

Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates Webcast
Jay Grobler, Infectious Disease Biology, Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Week 48 safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants (BRIGHTE Study) Poster
and
Phase 3 Study of fostemsavir in heavily treatment-experienced HIV-1 infected participants: BRIGHTE Week 48 subgroup analysis in randomized cohort
participants Poster

Peter Ackerman, Clinical Development, ViiV Healthcare, Branford, CT USA Webcast

Analysis of Patients Completing the Ibalizumab Phase 3 Trial and Expanded Access Program Webcast
Zvi Cohen, Medical Affairs, Theratechnologies Inc., Montreal, Canada

Distribution in cerebrospinal fluid (CSF) of cabotegravir (CAB) and rilpivirine (RPV) after intramuscular administration of long-acting (LA) injectable suspensions in HIV-1 infected patients Webcast Poster
Scott Letendre, Antiviral Center, University of California, San Diego, CA, USA

Congress Closing Remarks Webcast
Giulio Corbelli, EATG, Brussels, Belgium and Bologna, Italy
Andrew Phillips

Back to the top of the page